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Abstract
Background: Urea cycle disorders (UCDs) are inherited metabolic disorders that present with hyperammonemia,
and cause significant mortality and morbidity in infants and children. These disorders are not well reported in the
Indian population, due to lack of a thorough study of the clinical and molecular profile.
Results: We present data from two major metabolic centres in India, including 123 cases of various UCDs. The majority
of them (72/123, 58%) presented in the neonatal period (before 30 days of age) with 88% on or before day 7 of
life (classical presentation), and had a high mortality (64/72, 88%). Citrullinemia type 1 was the most common
UCD, observed in 61/123 patients. Ornithine transcarbamylase (OTC) deficiency was the next most common,
seen in 24 cases. Argininosuccinic aciduria was diagnosed in 20 cases. Deficiencies of arginase, N-acetylglutamate
synthase, carbamoyl phosphate synthetase, citrin, and lysinuric protein intolerance were also observed.
Molecular genetic analysis revealed two common ASS1 mutations: c.470G > A (p.Arg157His) and c.1168G > A
(p.Gly390Arg) (36 of 55 tested patients). In addition, few recurrent point mutations in ASL gene, and a deletion of the
whole OTC gene were also noted. A total of 24 novel mutations were observed in the various genes studied. We
observed a poor clinical outcome with an overall all time mortality of 63% (70/110 cases with a known follow-up),
and disability in 70% (28/40) among the survivors. Prenatal diagnosis was performed in 30 pregnancies in 25 families,
including one pre-implantation genetic diagnosis.
Conclusions: We report the occurrence of UCDs in India and the spectrum that may be different from the rest of the
world. Citrullinemia type 1 was the most common UCD observed in the cohort. Increasing awareness amongst
clinicians will improve outcomes through early diagnosis and timely treatment. Genetic diagnosis in the proband will
enable prenatal/pre-implantation diagnosis in subsequent pregnancies.
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Background
Urea Cycle Disorders (UCD) are a group of inborn errors of
metabolism seen frequently in tertiary care intensive care
units (ICUs) in view of the hyperammonemic
encephalopathy which is the most common presenting
feature. The overall incidence of UCD varies from 1:8000 to
1:44,000 births [1–4]. A more recent study from 3 countries
in Europe reported an estimated cumulative incidence of 1
in 51,946 for UCDs [5]. Incidence of UCD is not known in
India. All types of UCDs have been recognized.
The overall outcome of children with UCD remains poor,
even in the developed world where excellent infrastructure
and facilities are available [1, 6]. Children with UCD are
recognized after symptoms of hyperammonemia such as
lethargy and coma occur, thus leading to a significant
delay in diagnosis. This may happen in babies who are
screened as well, because neonatal hyperammonemic en-
cephalopathy often occur before neonatal screening test re-
sults are known. A delay in diagnosis results in either death
or neurodisability [7, 8]. This is exacerbated by a lack of
awareness amongst families and primary health care
physicians, causing a delay in seeking medical attention.
Additional factors in developing countries like India are in-
adequate facilities in most primary and secondary level hos-
pitals that contribute to a poor outcome. For instance,
laboratory ammonia assays are usually only available
even in tertiary hospitals. Therefore, a majority of babies
die without a diagnosis, or are recognized very late,
contributing to increased morbidity and mortality. An ac-
curate genetic diagnosis is essential not only for appropriate
management of the child, but also for genetic counseling in
the context of subsequent pregnancies and carrier testing.
So far, only a few mutations have been reported from India
[9–12]. The Indian population is a unique mix of several
cultures and sects, with considerable consanguinity. With
the distinctness of Indian gene pool, mutations may be dif-
ferent from other populations and perhaps recurrent in
some areas in view of closed community marriages, limiting
the gene pool to an ethnic group.
We present here our experience in diagnosis, genetic
testing and outcome after diagnosis of UCD in these
families. The data was collected from two major meta-
bolic centres in India.
Methods
Patient cohort
All neonates and children presenting with hyperammone-
mia and biochemical/clinical features of UCD since year
2001 till December 2017 were included in the cohort. The
patients were collected from two centres. In the first centre
at Sir Ganga Ram Hospital, New Delhi, they were chosen
either from the genetic clinic or from the molecular genet-
ics laboratory, which received samples for genetic testing
for UCD from referring clinicians. A biochemical diagnosis
of UCD was taken as the inclusion criteria. In some cases,
where DNA of the index patient was not available, parents
of the deceased patients were enrolled in the study, where
good clinical and biochemical data was available to fulfill
the diagnostic criteria. This centre was designated as Centre
1. In addition, cases from another referral centre (Centre 2)
in Mumbai (NIRMAN) were also included in this study.
All cases with complete clinical, biochemical and molecular
genetic data were taken. All parents or legal guardians pro-
vided their consent for DNA testing. All the tests were car-
ried out as part of clinical care as diagnostically indicated.
For selection of cases, information of clinical symp-
toms and hyperammonemia were solicited. This was
followed by biochemical analysis of amino acids by Tan-
dem mass spectrometry (MS/MS) on dried blood spots
(DBS) or Ultra/ High performance liquid chromatog-
raphy (U/HPLC) on plasma samples, and quantification
of urinary orotic acid by Gas chromatography-mass
spectrometry (GC-MS). To confirm the diagnosis of
UCD, genetic testing was carried out on DNA ex-
tracted from peripheral blood or dried blood spots
from affected children or their parents, where the
index case’s sample was not available. Sequencing of
the genes was performed either at Münster University
in Germany (2001–2008) or University Children’s
Hospital in Zurich (2008–2017) or at Sir Ganga Ram
Hospital (2008–2017) in New Delhi. Genetic testing
was done in cases from both centres. Prenatal diagno-
sis using chorionic villous sampling (CVS) or amnio-
centesis and mutation analysis was performed in
subsequent pregnancies of families.
Molecular studies for UCD gene mutations
DNA was isolated from human samples using standard
methods. PCR products were purified using MultiscreenR
PCRμ96 plate (MilliPore, USA). Bidirectional sequencing of
the coding exons and corresponding intron/exon boundar-
ies were set up using the same primers as for PCR, with
purified PCR products using BigDye® Terminator v 3.1 cycle
sequencing kit (Applied Biosystems, California). Sequencing
was carried out on ABI 3500Dx automated sequencer unit
(Applied Biosystems). Sequence chromatograms obtained
were analyzed with Chromas software (Technelysium,
Tewantin, Australia) and by manual inspection.
Obtained sequences were compared by blasting
them against the reference genomic sequences (for
ASS1: NM_000050, NP000041; for ASL: NM_000048,
NP_000039; for OTC: NM_000531, NP_000522). Bioinfor-
matics analysis was carried out to determine the functional
consequences of mutations and their effects on protein
structure by using different tools, e.g., Polyphen2 (genet-
ics.bwh.harvard.edu/pph2/), Mutation Taster (www.muta-
tiontaster.org/), or Sorting Intolerant from Tolerant (http://
provean.jcvi.org/index.php) [13–15].
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The probands with suspected OTC deficiency or
their mothers (in case of non-availability of DNA from
proband due to death prior to diagnosis), were evalu-
ated for deletions/duplications in the OTC gene by
(Multiplex ligation probe amplification) MLPA probe
mix (MRC Holland P079-OTC). Mutation analyses at
Münster or Zurich University were done as reported
[16–19].
For one patient, cDNA analysis of CPS1 gene was
performed. RNA-isolation and cDNA-synthesis was
performed using an established protocol [20]. Amplification
by PCR and direct sequencing of the carbamoylphosphate
synthetase 1 transcript was done in 6 overlapping
fragments. Ref. sequences: GenBank NM_001875.4 and
Ensembl ENSG00000021826, ENST00000233072.
Results
A total of 148 patients from the two centres were collected,
of whom 123 patients from 123 families fulfilled the criteria
and were included in the study. Nine patients from Centre
1, and 16 cases from Centre 2 were excluded because of
lack of a confirmed diagnosis. Seventy seven cases from
Centre 1 and 48 from Centre 2 fulfilled the criteria and
were enrolled. In the cohort of patients whose data was col-
lected, 82% have been after year 2007.
The diagnosis was established in all 123 patients; 61 had
citrullinemia type 1, 26 patients had OTC deficiency, 20
were of argininosuccinic aciduria (ASA), 9 had arginase de-
ficiency, 3 had carbamoyl phosphate synthetase (CPS1), 2
had N-acetyl glutamate synthase (NAGS) deficiency and
one patient each had lysinuric protein intolerance (LPI) and
citrin deficiency (Table 1). All patients were diagnosed bio-
chemically by quantitative amino acid analysis on dried
blood spots (MS/MS) or in plasma (U/HPLC), except for
LPI where both plasma and urine amino acid quantitation
was performed by HPLC (see Additional file 1).
Clinical details were available for all 123 patients. Full
clinical, laboratory, and outcome details are available in
Table 1 Clinical features and outcomes of the various urea cycle disorders
Types of UCD ASS1-D ASL-D OTC-D ARG-D CPS1-D NAGS-D Citrin-D LPI Total
Total Numbers 61 20 26 9 3 2 1 1 123
Consanguinity 9 (n = 54) 7 (n = 19) 2 (n = 25) 5 (n = 9) 1 (n = 2) 1 (n = 2) 0 (n = 1) 1 (n = 1) 26 (n = 113)
Positive family history 14 (n = 56) 9 (n = 20) 12 (n = 24) 2 (n = 9) 0 (n = 3) 1 (n = 1) 0 (n = 1) 0 (n = 1) 38 (n = 115)
Age group
Neonatal 44 13 11 0 2 2 0 0 72
Infancy 6 3 4 0 0 0 0 0 13
> Infancy (> 1 year) 11 4 11 9 1 0 1 1 38
Clinical presentation
Neonatal or intermittent
encephalopathy, or seizures
51 17 19 0 3 1 0 1 92
Liver disease
(deranged liver enzymes)
6 5 2 0 0 0 0 0 13
Failure to thrive 3 1 1 1 0 0 0 1 7
Developmental delay 6 5 7 9 0 0 0 0 27
Other neuropsychiatric/
behavioural/ ataxia/ spasticity
symptoms
Nil 0 4 6 1 0 1 0 12
Mutations performed 55 16 22 5 3 2 1 1 105
Results obtained 55 15 18 5 3 2 1 1 100
Outcome
Death 44 12 11 0 1 2 0 0 70
Alive 10 5 14 8 1 0 1 1 40
Development: Delayed 7 5 7 8 1 0 0 0 28
Development: Normal or
near normal
2 1 7 0 0 0 1 1 12
Diet -Protein restriction+
medications
6 5 10 8 1 0 0 1 31
Lost to follow up/ not known 7 3 1 1 1 0 0 0 13
ASS1-D Argininosuccinate synthetase type 1 deficiency, ASL-D Argininosucccinate lyase deficiency, OTC-D Ornithine transcarbamylase deficiency, ARG-D Arginase
deficiency, CPS1-D CPS1 deficiency, NAGS-D N-acetyl glutamate synthase deficiency, Citrin-D Citrin deficiency, LPI Lysinuric protein intolerance
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Additional file 1. Approximately three-fifth of patients
(72/123, 58%) presented in the first 30 days of life (neo-
natal period), 88% of whom presented on or before day
7 of life (classical presentation). Thirteen cases presented
in infancy between 1 and 12 months of life, and 38 after
the first year of life. Overall male to female ratio was 1.7:1
(2.25:1 in OTC deficiency, 1.65:1 in non-OTC deficiency).
Consanguinity and a positive family history were noted in
23% (26/113) and 33% (38/115) of families, respectively.
All families were unrelated except one where a
non-consanguineous couple visited our clinic after losing
their daughter on day 6 of life with encephalopathy and
no other investigations. Husband’s niece was detected to
have citrullinemia type 1. Based on the history, the couple
was tested and detected to be carriers of citrullinemia type
1. Apart from this, there were no related families.
Detailed description of all cases including demography,
clinical presentations, family history, biochemical investi-
gations, outcomes and prenatal diagnosis data (for subse-
quent pregnancies in parents of probands) are shown in
Additional file 1: Table S1. A large number of cases pre-
sented with encephalopathy with or without seizures (94/
123, 76%), either in neonatal period or later (Table 1). Half
of the patients in the late onset group presented with de-
velopmental delay (22/51, 43%). A significant number of
children had features of liver disease (10.5%) and failure to
thrive (3%) (Table 1).
Outcome analysis
Outcome data was available from 110 cases. Of these, 70
died and 12 patients are healthy and developing nor-
mally. The remaining 28 patients are surviving with
varying degree of disability (Fig. 1 and Table 1).
Citrullinemia type 1 was the most frequently ob-
served UCD and showed the worst outcome. Of 55
patients for whom outcome was known, 44 died
(81.5%), 7 children survived with disability ranging
from minor learning difficulties to severe global delay
and seizures, and 3 children survived without disabil-
ity: 2 of whom received liver transplantation, and 1
patient with a milder presentation of neonatal chole-
stasis and liver dysfunction that resolved over time.
All except 2 deaths occurred in the first episode of
illness in neonatal period. In the two children who
survived the initial insult in neonatal period, there
was severe failure to thrive, and death because of
relentless progression of disease with intercurrent
illnesses.
Outcomes in ASL and OTC deficiency cases were also
poor with a total mortality of 50% (23/46 cases). In ASL
deficiency survivors, all except 1 had some degree of dis-
ability. In OTC deficiency survivors, 5 of 8 girls and 2 of 6
boys have developmental delay and 3 girls and 4 boys were
healthy (Table 1, Additional file 1: Table S1). All the chil-
dren who are doing well presented with mild symptoms of
episodic vomiting.
Molecular genetic studies
Molecular studies could be performed in 105 patients/fam-
ilies. All tests were targeted sequencing of genes based on
preliminary biochemical diagnosis. Pathogenic or likely
pathogenic variants were noted in 100 cases. Molecular
analysis for specific genes did not reveal any pathogenic
variant in 5 cases. Details of mutations are listed in Tables 2,
3 and 4. Table 5 provides details of clinical presentation,
and gene studies performed in mutation negative patients.
Fig. 1 Flowchart showing outcomes of UCD patients
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Table 2 Details of mutations in all patients
Gene Mutation Number of cases No.
of
alleles
Reference ExAC data base
(allele frequency)Position DNA Protein/ mRNA Type Homo
zygous
Hetero/ Hemi
zygous
ASS1 Exon 5 c.190G > A p.Val64Ile Missense 1 1 3 Novel 0.00003303
Exon 5 c.269G > A p.Gly90Asp Missense 1 0 2 Novel NA
Exon 5 c.271A > C p.Thr91Pro Missense 1 0 2 Novel 0.00003324
Exon 5 c.299G > A p.Arg100His Missense 0 1 1 [30] 0.0001597
Exon 5 c.349G > T p.Gly117Cys Missense 1 0 2 [30] NA
Exon 5 c.350G > A p.Gly117Asp Missense 0 1 1 [36] NA
Exon 6 c.370G > A p.Asp124Asn Missense 1 1 3 [37] NA
Exon 7 c.470G > A p.Arg157His Missense 12 1 25 [38] 0.00009932
Exon 9 c.570T > A p.Tyr190Ter PTC** 0 1 1 Novel NA
Exon 12 c.793C > T p.Arg265Cys Missense 3 1 7 [39] 0.000008262
Exon 12 c.815G > A p.Arg272His Missense 2 0 4 [40] NA
Exon 13 c.910C > T p.Arg304Trp Missense 2 0 4 [38] 0.00004119
Exon 14 c.970G > A p.Gly324Ser Missense 1 0 2 [38] 0.00004952
Exon 14 c.1088G > A p.Arg363Gln Missense 0 1 1 [30] 0.000008792
Exon 15 c.1139delA p.Glu380Argfs*20 Deletion
sbp*
2 1 5 Novel NA
Exon 15 c.1168G > C p.Gly390Arg Missense 23 1 47 [38] NA
Total 50 10 110
ASL Exon 3 c.89_94delinsGTCGTA p.Tyr30_Asp31delinsCysArg DEL INS*** 0 1 1 Novel NA
Exon 5 c.326C > G p.Thr109Arg Missense 0 1 1 Novel NA
Exon 5 c.337C > T p.Arg113Trp Missense 1 0 2 [16] 0.00006783
Exon 7 c.509G > A p.Ser170Asn Missense 0 2 2 [41] NA
Exon 8 c.593C > T p.Pro198Leu Missense 1 0 2 Novel NA
Exon 9 c.637C > T p.Arg213Ter PTC 0 3 3 [42] 0.000008417
Exon 9 c.649C > T p.Arg217Ter PTC 1 0 2 Novel 0.000008443
Exon 11 c.733T > C p.Trp245Arg Missense 0 1 1 Novel NA
Exon 11 c.749T > A p.Met250Lys Missense 0 1 1 Novel 0.00000854
Exon 12 c.857A > G p.Gln286Arg Missense 2 1 5 [43] 0.00007499
Exon 12 c.913G > A p.Gly305Arg Missense 0 1 1 Novel NA
Exon 12 c.967A > G p.Lys323Glu Missense 1 0 2 Novel NA
Exon 12 c.978G > C p.Gln326His Missense 0 1 1 [41] 0.00003771
Exon 16 c.1153C > T p.Arg385Cys Missense 1 0 2 [44] 0.00006732
Exon 17 c.1297A > C p.Ser433Arg Missense 0 2 2 [41] NA
Exon 17 c.1300G > T p.Val434Leu Missense 0 2 2 [41] 0.000008284
Total 7 16 30
OTC Exon 1 c.274C > T p.Arg92Ter PTC 0 1 1 [45] NA
Exon 1 c.275G > A p.Arg92Gln Missense 0 1 1 [45] NA
Exon 4 c.386G > A p.Arg129His Missense 0 3 3 [32] NA
Exon 5 c.421C > T p.Arg141Ter PTC 0 1 1 [33] NA
Exon 5 c.535C > T p.Leu179Phe Missense 0 1 1 [46] NA
Exon 6 c.604C > T p.His202Tyr Missense 0 1 1 [47] NA
Exon 7 c.674C > T p.Pro225Leu Missense 0 2 2 [48] NA
Exon 7–8 c.773_790del p.Asn258_263del Deletion 0 1 1 Novel NA
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A total of 58 different mutations were detected in
100 patients, 16 of which were observed in ASS1 gene
and ASL gene each, 12 mutations in OTC gene, and 6
mutations each in ARG1 gene, 3 in CPS1, 2 in NAGS
and SLC25A13 genes, and one in SLC7A7 gene
(Table 2). Twenty four mutations were novel. Of 100
patients in whom the diagnosis was genetically con-
firmed, 67 were homozygous and 15 were compound
heterozygous, 12 were hemizygous and 6 were hetero-
zygous (for an OTC mutation).
ASS1 gene sequencing was performed in 55 out of 61
cases. The two most common mutations, c.470G >A
(p.Arg157His) and c.1168G > A (p.Gly390Arg) were ob-
served in 72 alleles out of a total of 110 alleles (65.5%).
The missense mutation, c.1168G >A occurred twice more
frequently (47/110 alleles [42.7%]) than c.470G >A (25/
110 alleles [22.7%]). Five mutations were novel (Table 3).
Sequencing of ASL gene revealed more varied findings
with 16 mutations in 15 cases. Interestingly, all mutations
were in compound heterozygous states in the 8 cases from
Centre 1 whereas all mutations were noted in homozy-
gous form in the patients from Centre 2. Four mutations
were noted to be recurrent: c.509G > A (p.Ser170Asn),
c.637C > T (p.Arg213Ter), c.1297A > C (p.Ser433Arg) and
c.1300G > T (p.Val434Leu), occurring in 2, 3, 2 and 2 al-
leles, respectively. Eight mutations were noted to be novel.
OTC gene sequencing was performed in 22 of 26 cases.
No mutation was identified in 4 cases (one male, 2 female
probands and 1 carrier mother) after full sequencing of
OTC gene as well as MLPA analysis for deletions/duplica-
tions. The most common mutation noted was a whole
gene deletion in 4 cases, accounting for 22.2% (4/18)
cases. Rest of mutations were single nucleotide substitu-
tions, missense or nonsense mutations. Pathogenic vari-
ants were also identified in arginase deficiency (5 cases),
CPS1 deficiency (3 cases), two cases of NAGS deficiency,
one case each citrin deficiency [10] and LPI [11]. All
pathogenic variants in ARG1 and NAGS genes were novel
Table 2 Details of mutations in all patients (Continued)
Gene Mutation Number of cases No.
of
alleles
Reference ExAC data base
(allele frequency)Position DNA Protein/ mRNA Type Homo
zygous
Hetero/ Hemi
zygous
18 bp
Exon 8 c.805G > A p.Gly269Arg Missense 0 1 1 Novel NA
Exon 8 c.829C > T p.Arg277Trp Missense 0 1 1 [49] NA
Exon 8 c.835C > T p.Gln279Ter PTC 0 1 1 [50] NA
Exon
1–10
Whole gene
deletion
Large
deletion
0 4 4 [51] NA
Total 0 18 18
ARG1 Exon 1 c.2 T > C p.Met1? Initiation
codon
1 0 2 Novel NA
Exon 3 c.132_146del p.Gln44_Lys48del Deletion
15 bp
0 1 1 Novel NA
Exon 3 c.295G > A p.Gly99Arg Missense 0 1 1 Novel 0.00001658
Exon 5 c.551delC p.Pro184Leufs*7 PTC 1 0 2 Novel NA
Intron 7 c.802 + 2 T > G Splice site Splice site 1 0 2 Novel NA
Exon 8 c.877delG p.Val293Ter PTC 1 0 2 Novel NA
Total 4 2 10
CPS1 Intron 3 c.236 + 4A > G
(NM_001875.4)
Splice site Splice site 1 0 2 Novel
Exon 19 c.2339G > A p.Arg780His Missense 1 0 2 [52] 0.00003304
Exon 21 c.2623A > G p.Lys875Glu Missense 1 0 2 [18] 0.002427
NAGS Exon 3 c.787G > T p.Glu263Ter PTC 1 0 2 Novel NA
Exon 4 c.991C > T p.Gln331Ter PTC 1 0 2 Novel NA
SLC25A13 Exon 7 c.650delT p.Phe217Serfs*33 Deletion
sbp
0 1 1 [11]
Exon 9 c.869T > C p.Ile290Thr Missense 0 1 1 [11] 0.000008256
SLC7A7 Exon 15 c.158C > T p.Ser53Leu Missense 1 0 2 [12] NA
GRAND TOTAL 67 48 100
*sbp single base pair, **PTC Premature termination codon, ***DEL INS Deletion insertion
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(Tables 2 and 3). Another novel pathogenic variant was
noted in CPS1 gene. The pathogenicity of this variant,
c.236 + 4A >G (NM_001875.4) was checked via RNA
studies at Zurich. On RNA level, as a consequence of this
splice-site mutation, two alternatively spliced transcript
variants were observed: the majority of transcripts showed
complete skipping of exon 2 (r.127_236del, p.Ala43-
Valfs*7) but also partial skipping of exon 2 (r.206_236del,
p.Glu70Thrfs*70) was observed. Both parents are carriers
of the mutation, confirming obligate heterozygosity.
Prenatal diagnosis
Mutation analysis led to successful prenatal diagnoses in
30 pregnancies in 25 families (Table 6). This included one
couple that opted for pre-implantation genetic diagnosis
(PGD) after having an affected fetus in a preceding preg-
nancy. In this case the result was normal, and the couple
delivered a healthy baby. Of the 29 prenatal analyses, 11
pregnancies were found to carry fetuses with no mutation
(normal), 13 with carrier fetuses (including 2 OTC female
carriers, both of whom are doing well after birth) and 5
carried affected fetuses. Amongst 19 pregnancies in fam-
ilies with ASS or ASL deficiency, 4 pregnancies were
found to have fetuses affected with disease (21%).
Discussion
Urea cycle disorders occur universally with varying fre-
quencies in different populations [1, 21–23]. While OTC
Table 3 Evaluation of pathogenicity of novel variants using in-silico prediction tools
Gene Mutation Protein change Mutation taster LRT SIFT PROVEAN DANN ExAC dbSNP
ASS1 c.190G > A p.Val64Ile Disease causing Neutral Tolerated Neutral 0.9791 0.00003303 556,297,791
c.269G > A p.Gly90Asp Disease causing Unknown Damaging Damaging 0.9985 Not Present 1,422,867,920
c.271A > C p.Thr91Pro Disease causing Unknown Damaging Damaging 0.9963 0.00003324 769,018,733
c.570C > A p.Tyr190Ter Disease causing Unknown NA NA 0.9957 Not Present Not Present
c.1139delA p.Gln380Argfs*20 Disease causing NA NA NA NA Not Present 1,213,378,896
ASL c.89_94delinsGTCGTA p.Tyr30_Asp31delinsCysArg Disease causing NA NA NA NA Not present Not present
c.326C > G p.Thr109Arg Disease causing Deleterious Damaging Damaging 0.9938 Not present Not Present
c.593C > T p.Pro198Leu Disease causing Deleterious Damaging Damaging 0.9992 Not Present 1,282,829,485
c.649C > T p.Arg217Ter Disease causing Neutral NA NA 0.9972 0.000008443 369,879,957
c.733T > C p.Trp245Arg Disease causing Deleterious Damaging Damaging 0.9941 Not present Not Present
c.749T > A p.Met250Lys Disease causing Deleterious Damaging Damaging 0.9791 Not present 754,634,171
c.913G > A p.Gly305Arg Disease causing Deleterious Damaging Damaging 0.9993 Not present Not Present
c.967A > G p.Lys323Glu Disease causing Deleterious Damaging Damaging 0.9987 Not present Not Present
OTC c.773_790del p.Asn258_263Del Disease causing NA NA NA NA Not present Not Present
c.805G > A p.Gly269Arg Disease causing Deleterious Damaging Damaging 0.9992 Not Present Not Present
ARG1 c.2T > C p.Met1Thr Disease causing Deleterious Damaging Neutral 0.9809 Not Present Not Present
c.132_146del p.Gln44_Lys48del Disease causing NA NA NA NA Not Present Not Present
c.295G > A p.Gly99Arg Disease causing Deleterious Damaging Damaging 0.9993 0.00001658 753,829,097
c.551delC p.Pro184Leufs*7 Disease causing NA NA NA NA Not Present Not Present
c.802 + 2 T > G Splice site Disease causing NA NA NA 0.9948 Not Present Not Present
c.877delG p.Val293Ter Disease causing NA NA NA NA Not Present Not Present
CPS1 c.254 + 4A > G Splice site Disease causing NA NA NA 0.9747 Not Present Not Present
NAGS c.787G > T p.Glu263Ter Disease causing Deleterious NA NA 0.9963 Not Present Not Present
c.991C > T p.Gln331Ter Disease causing Deleterious NA NA 0.9973 Not Present 1,445,639,047
Mutation Taster: An in silico prediction tool for the pathogenicity of a variant based on evolutionary conservation, splice-site, mRNA, protein and
regulatory features. The potential is predicted by a naive Bayes classifier
LRT: Likelihood ratio test (LRT) predicts deleterious variants through identification of highly conserved amino acid regions using a comparative
genomics data set of 32 vertebrate species. Range 0 to 1
SIFT: SIFT (sorts intolerant from tolerant) is an in silico prediction tool for nonsynonymous variants based on sequence homology derived from
closely related sequences collected through PSI-BLAST. Range 0 to 1 with values less than 0.05 usually considered intolerant. 40% of the values in
this database are below 0.01
PROVEAN: Protein Variation Effect Analyzer is an in silico tool that predicts how nonsynonymous, MNP, or in-frame indel variant will affect a
protein’s biological function. The prediction is based on alignment-based scores derived from pairwise sequence alignments between the query
sequence and each of the related sequences at the protein level. Range − 14 to + 14
DANN: DANN is a pathogenicity scoring methodology developed by Daniel Quang, Yifei Chen and Xiaohui Xie at the University of California,
Irvine. It is based on deep neural networks. The value range is 0 to 1, with 1 given to the variants predicted to be the most damaging
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deficiency has been reported to be the most commonly
occurring UCD, citrullinemia type 1 is reported to be
less common [3, 5, 24]. In contrast, in our cohort, citrul-
linemia type 1 contributed to about half (61/123, 49.6%),
thus making citrullinemia type 1 the most commonly oc-
curring UCD in this cohort. The data was pooled from
two centres, both showing similar results independently.
OTC deficiency was observed with lower frequency in
the cohort. In fact, the total incidence for OTC defi-
ciency was less than half of that found for citrullinemia
type 1. Although suspected in few additional patients
(hyperammonemia with high urinary orotic acid ex-
pected in OTC deficiency), there was insufficient evi-
dence to prove OTC deficiency in some patients because
of the difficulty in performing enzyme based diagnosis
(which would have required a liver biopsy) or due to lack
of mutations in the OTC gene despite full gene study
(sequencing as well as testing for larger deletions and
duplications by MLPA). These difficulties are however
well known and described earlier in large studies [25].
Many factors contributed to the failure to achieve a de-
finitive diagnosis in all patients: the lack of availability of
enzyme diagnostics at any centre in India, the invasive-
ness of the test (liver biopsy) along with difficulty in
shipment of liver biopsy specimens in frozen state to an-
other centre abroad, and the overall cost involved. It is
therefore likely that cases of OTC deficiency are being
missed in India, as known from literature [25].
The situation is different in the case of citrullinemia type
1, where a very high citrulline level on dried blood spot
MS/MS can be reliably detected leading to further gene
studies confirming the diagnosis. Presence of ASA in
blood or urine is indicative of ASL deficiency, and for ele-
vated plasma arginine of arginase deficiency.
Urea cycle disorder commoner than OTC deficiency
has also been noted in Saudi Arabian population,
where ASL deficiency has been described as the most
common UCD. Consanguinity in this particular popu-
lation seems to be one leading explanation [26]. Paral-
lels can be drawn with the Indian population where
both consanguinity and closed community marriages
are the norm, leading to genetic isolates. This may be
a part explanation to citrullinemia type 1 being more
common in India. In our cohort, consanguinity was
noted in 23% families. Consanguinity and close com-
munity marriages are important factors leading to in-
creased occurrence of recessive disorders, at least in
India [27].
Table 4 Types of mutations detected
Total number of patients with mutations 100
Number of patients with homozygous mutations 67
Total number of mutations 58
Total number of novel mutations 24
Missense mutations 39
Premature termination codon 10
Initiation codon mutation 1
Splice site mutation 2
Small insertions/ deletions 5
Large deletion 1
Table 5 Patients in whom molecular studies showed no mutations
Gene
studied
S.No
(as in
Additional
file 1)
Age at
presentation
Sex
(proband)
Consanguinity Family
history
of similar
disease
Clinical features
in proband
Amino acids levels
by MS/MS on dried
blood spot (μmol/l)
GC-MS in urine Ammonia
level
(in μmol/l)
ASL 78 4 days Male No No Neonatal
encephalopathy,
convulsions,
lethargy, reduced
feeding
Citrulline- 2557,
ASA- 753.19
Increased
orotate 393
NK
OTC 86 4 days Male No Yes,
previous
2
Neonatal
encephalopathy
and deaths
NK Allopurinol
challenge test in
mother - increase
in orotate
NK
93 5 days Male No Yes Neonatal
encephalopathy
and death
NK Increased orotate High
96 2 years Female No Yes,
elder
sister
Encephalopathy,
Febrile illness with
high ammonia
Normal amino acid
levels Citrulline 15,
arginine 15,
ornithine 146
Increased orotate High 1600
98 1.5 years Female No No Encephalopathy,
Vomiting, awkward
behaviour, high
ammonia
NK Increased orotate Level NK
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In our study, 10 couples (and 6 expectant mothers in
case of OTC deficiency) were tested in absence of a sam-
ple from index patient, and their gene study detected
heterozygous mutations, suggesting an accurate diagno-
sis in their probands. In seven couples, citrullinemia type
1 was suspected based on elevated plasma citrulline in
index patient and these couples were only tested for mu-
tations in ASS1 gene.
The presentation in most Indian children was similar to
what is known in literature, with both neonatal classic form
and late onset presentations. In our cohort, the neonatal
classic presentation was more common in all UCDs except
arginase and citrin deficiency. This finding is somewhat dif-
ferent from other studies where majority of presentations
are beyond first 30 days of life [1, 28, 29]. The more com-
mon early presentation in our cohort may have been a bias
because neonatal cases are recognized more easily in view
of a careful medical supervision in the neonatal period. A
recent study from Europe reported 50 patients of UCD de-
tected both symptomatically (39/50) and NBS/presympto-
matically (11/50). In this cohort, 28 of 39 symptomatically
detected patients presented with neonatal encephalopathy,
Table 6 Prenatal diagnosis in families with UCDs
S. No (as per
Additional file 1)
Diagnosis
in proband
Age at presentation
in probands
Consanguinity
among parents
Mutations
in proband
Protein change Number
of PND
Results of PND
5 ASS1-D 6 days No c.1168G > A p.Gly390Arg Once Not affected (carrier)
7 ASS1-D 5 days Yes c.470G > A p.Arg157His Twice One affected, one
unaffected (carrier)
10 ASS1-D 5 days No c.1168G > A p.Gly390Arg Once Not affected
16 ASS1-D 7 days No c.570T > A
c.350G > A
p.Tyr190Ter &
p.Gly117Asp
Once Affected
17 ASS1-D 4 days No c.1139delA p.Glu380Arg
fs*20
Once Not affected (carrier)
18 ASS1-D 4 days No c.470G > A p.Arg157His Once,
one PGD
Affected, PGD pregnancy
healthy baby
19 ASS1-D 6 days Yes c.970G > A p.Gly324Ser Once Not affected (carrier)
22 ASS1-D 2 days Yes c.470G > A p.Arg157His Once Not affected (carrier)
27 ASS1-D 4 days No c.1168G > A p.Gly390Arg Once Not affected
30 ASS1-D 5 days No c.470G > A p.Arg157His Once Not affected (carrier)
33 ASS1-D 3 days No c.1168G > A p.Gly390Arg Once Not affected
35 ASS1-D Neonatal No c.1168G > A p.Gly390Arg Once Not affected
61 ASS1-D Neonatal No c.1168G > A p.Gly390Arg Once Not affected (carrier)
62 ASL-D 4 days No c.509G > A
c.1297A > C
p.Ser170Asn
p.Ser433Arg
Twice Affected once, not
affected second time
65 ASL-D 5 days No c.637C > T
c.1300G > T
p.Arg213Ter
p.Val434Leu
Once Not affected (carrier)
70 ASL-D 9 days Yes c.913G > A
c.749 T > A
p.Gly305Arg
p.Met250Lys
Once Not affected (carrier)
87 OTC-D 6 days No c.674C > T p.Pro225Leu Twice Not affected (once
carrier, once no mutation)
91 OTC-D 3 days Yes whole gene deletion
(mother tested)
Once Carrier female
92 OTC-D 3 days No c.274C > T p.Arg92Ter Once Not affected
94 OTC-D 5 days Yes c.421C > T p.Arg141Ter Twice First affected male,
second carrier female
97 OTC-D 2 days No whole gene deletion
(mother tested)
Once Not affected
101 OTC-D 5 years No whole gene deletion
(mother tested)
Once Not affected
119 CPS1 -D NK NK c.2623A > G p.Lys875Glu Once Not affected
120 NAGS-D NK NK c.991C > T p.Gln331Ter Once Not affected
121 NAGS-D Neonatal Yes c.787G > T p.Glu263Ter Once Not affected (Carrier)
NK: Not known, PGD: Pre-implantation genetic diagnosis
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thus corroborating with our observation of a neonatal
presentation being more common [5]. The high mortality
among the neonatal encephalopathy group in our cohort
was similar to the cohort reported from Europe [5].
A family history of previous sibling deaths was present in
approximately 33% of families. This highlights the immense
burden of the disease on the families, and the ignorance as
well as lack of facilities denying these families of an oppor-
tunity for early diagnosis and prompt treatment. This
would have prevented the suffering, either by successful
treatment of the index child or by prenatal diagnosis.
Molecular diagnosis thus helped the families in prevention
of recurrence of this difficult group of disorders.
Molecular analysis revealed several interesting findings
besides being immensely helpful in family counseling.
For ASS1 gene, there were two common mutations,
p.Gly390Arg and p.Arg157His which constituted 65.5%
of cases. These two are previously reported mutations
and are present globally [30]. Most common mutation
seen in multiple ethnic group is p.Gly390Arg except in
the east Asian population where another mutation,
c.421-2A > G is the commonest [31]. Another mutation,
p.Arg265Cys seen in our population was common to the
Japanese population [31]. There seemed to be a good
genotype-phenotype correlation, which is in agreement
with reported literature [24]. Two recurring mutations,
p.Arg213Ter and p.Ser170Asn, were found in ASL gene.
In a significant number of OTC deficiency patients, a
whole gene deletion was detected. In this disorder, whole
gene deletions as well as nonsense mutations were noted
either in neonatally presenting severely affected males or
in manifesting females, while missense mutations were
noted in mildly affected boys. This finding is also in
agreement with literature [21, 32, 33]. The mutation
p.Arg129His, showing a mild phenotype with excellent
prognosis, has previously been described [34]. Similarly,
p.Arg277Trp is known to be a mild mutation, reported
even in male transmission [35].
Molecular analysis enabled successful prenatal diag-
nosis in 30 pregnancies with no false negative results.
This is an effective way of reducing the disease-related
morbidity and mortality, until appropriate facilities are
made available for early diagnosis and treatment.
Conclusions
This is the first comprehensive report of mutations in
UCDs from the Indian subcontinent. Increasing avail-
ability of gene sequencing has enabled higher numbers
of prenatal diagnosis for UCDs. Establishing a precise
molecular diagnosis by mutation analysis is helpful not
only for accurate genetic counseling but also for accur-
ate carrier testing, which is an efficient way for reducing
the morbidity and mortality associated with the disease
through prenatal diagnosis.
Additional file
Additional file 1: Details of clinical, biochemical and molecular analysis
and of outcomes and prenatal diagnoses in each patient in the study.
The data provides complete information about each patient enrolled in
the study. This includes the demographic details, clinical and family
history, the laboratory investigations (biochemical as well as mutation
analysis), an outcome data and information about prenatal diagnosis in
the particular family. Each patient is assigned a number, and all patients
belong to different families, thus 123 patients from 123 families were
enrolled. Data is pooled from two genetic centres differentiated by use
of different color font in the table – black for centre 1 and maroon for
centre 2. (XLSX 30 kb)
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